Details for Patent: 11,236,121

Which drugs does patent 11,236,121 protect, and when does it expire?

Patent 11,236,121 protects ZURZUVAE and is included in one NDA.

This patent has fifty-one patent family members in twenty-four countries.

Summary for Patent: 11,236,121

Title:	Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
Abstract:	This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
Inventor(s):	Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
Assignee:	Sage Therapeutics Inc
Application Number:	US16/326,977
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,236,121
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 11,236,121

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-001	Oct 31, 2023		RX	Yes	No				Y
Biogen	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-002	Oct 31, 2023		RX	Yes	No				Y
Biogen	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-003	Oct 31, 2023		RX	Yes	Yes				Y

International Family Members for US Patent 11,236,121

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109393
Argentina	125320
Argentina	125321
Australia	2017315682